<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/28/2022 6:28:22 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 3a67a153-b731-48d4-9a07-5e159bb72da4 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rsls="http://reshapelifesciences.com/20221221" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityCentralIndexKey" id="Tc_3C8mNrTO3kufgqi0O4okMg_2_1">0001427570</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:AmendmentFlag" id="Tc_3pzbJsHZC0OOQUvzUAa1pw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:CurrentFiscalYearEndDate" id="Tc_ecLrhywgtke2mO4EXJK3Bg_4_1">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rsls-20221221.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427570</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-21</xbrli:startDate><xbrli:endDate>2022-12-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 12pt 0pt;"><span style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:1pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:double;visibility:hidden;">&#8203;</span></p><a id="_3f8fd93b_59ca_4403_a42d_bda44b4fbae7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Washington, D.C.  20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:DocumentType" id="Narr_D8Wo38jroUitpMGQpYbwEQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_5iwfMJNg4UWnNht2Rq7-cg"><b style="font-weight:bold;">December 21, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityRegistrantName" id="Narr_EMkOMSa350uMJmd1rrYBxg"><b style="font-weight:bold;">RESHAPE LIFESCIENCES INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_3539c1dc_e6fb_4793_a175_925bb1664461"></a><a id="Tc_wIMzsisBOEO-viKOpACTHQ_2_0"></a><a id="Tc_xhrGUId-6EmpQr6tIVEomA_2_1"></a><a id="Tc_5uFeVom7hkOhaQSng57Ctg_2_2"></a><a id="Tc_bk_3vblJOU-lNdM_SKdtlg_4_0"></a><a id="Tc__fysIpLCW0y7DK1eGDWBsw_5_0"></a><a id="Tc_KZMPpiLCnECSunKOuuX2WQ_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 6pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_AYoEk88BH0qxTP7M9ewnWQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityFileNumber" id="Tc_-Ht4NiFUXEKkDA_caluDCQ_1_1"><b style="font-weight:bold;">1-37897</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityTaxIdentificationNumber" id="Tc_sTHLbbNAAUSz3qoUtfdfFA_1_2"><b style="font-weight:bold;">26-1828101</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 6pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission&#160;File&#160;Number)</p></td><td style="vertical-align:top;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification&#160;No.)</p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityAddressAddressLine1" id="Narr_DYyEry_wrk6CooVGfYlzYQ"><b style="font-weight:bold;">1001 Calle Amanecer</b></ix:nonNumeric> <br /><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityAddressCityOrTown" id="Narr_Pe4Z5GlP4E-vtGRb9n0N8Q"><b style="font-weight:bold;">San Clemente</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityAddressStateOrProvince" id="Narr_srHrqRpFY0GUDwmzMVDqFw"><b style="font-weight:bold;">CA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:EntityAddressPostalZipCode" id="Tc_NbeuPZXVLkGI-ryS8MabSA_4_2"><b style="font-weight:bold;">92673</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 5pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:CityAreaCode" id="Narr_PqVBfvORF0C_BqwZ5o4gyQ"><b style="font-weight:bold;">949</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:LocalPhoneNumber" id="Narr_eG4rrZu3i0OBeq8sz4rkjA"><b style="font-weight:bold;">429-6680</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_fEkdaYzbWU6xi2Bncdow4g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_zGk3YjlSJk6HAUJBt4yWBQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_FiaxtP_4Z0-073gvk9w-2w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_fW1H42ezTEmdBb5VfCbM8A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act: </b></p><a id="_11b8e7b5_145d_43c4_90aa_74e9e9a83797"></a><a id="Tc_9UY14vlHjkaXLaNrem964Q_1_0"></a><a id="Tc_lsLYn6iA6UWZH2Rbv5GJiQ_1_1"></a><a id="Tc_QynRGF-7jEqDWKlhEBEEXA_1_2"></a><a id="Tc_SjeNgWRK50asswIphb_9aw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Title of Class</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0pt -3.65pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;Trading Symbol</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-size:6.5pt;font-weight:bold;">Name of Exchange on which Registered</b></p></th></tr><tr><td style="vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:Security12bTitle" id="Tc_JfuYmB7PT0meaoR8KJ3-zA_2_0"><span style="font-size:9pt;">Common stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" name="dei:TradingSymbol" id="Tc_uVKHDRy-LEeE9tQnva4M2A_2_1"><span style="font-size:9pt;">RSLS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">The </span><ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_C_70nLErV0KtQ-EaNqGeKw"><span style="font-size:9pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:9pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_12_21_2022_To_12_21_2022_H9Pymyzuq0aDczSkMhuMfw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_FIZB77kpCUi3PqpVXn7g7A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_0b609783_2075_4ac3_8c7a_7934005295fb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3.03&#160;&#160;&#160;&#160;&#160;Material Modification to Rights of Security Holders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information contained in Item 5.03 below is incorporated by reference into this Item 3.03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3f6ce47e_6999_4a11_9502_72684bfcc5b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.03&#160;&#160;&#160;&#160;&#160;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">On December 21, 2022, ReShape Lifesciences Inc. (the &#8220;Company&#8221;) filed a Certificate of Amendment (the &#8220;Certificate of Amendment&#8221;) to its Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse split of the Company&#8217;s outstanding common stock, $0.001 par value per share (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective for trading purposes upon the commencement of trading on December 23, 2022, at which point the Company&#8217;s common stock began trading on a split adjusted basis on the Nasdaq Capital Market. As a result of the Reverse Stock Split, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">As a result of the Reverse Stock Split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the Company&#8217;s outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;white-space:pre-wrap;">The Certificate of Amendment also increased the number of shares of common stock that the Company is authorized to issue under the Certificate of Incorporation from 100,000,000 to 300,000,000 shares. The Reverse Stock Split does not reduce the number of authorized shares of common stock and preferred stock under the Certificate of Incorporation. Therefore, the effect of the Reverse Stock Split is to increase the number of shares of common stock and preferred stock available for issuance relative to the number of shares issued and outstanding.  The Reverse Stock Split will not alter the par value of the common stock or preferred stock or modify any voting rights or other terms of the common stock or any series of preferred stock. The Reverse Stock Split and increase in authorized shares of common stock were approved by the Company&#8217;s stockholders at its annual meeting of stockholders held on December 14, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">As set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Mirroring Preferred Stock of the Company, the Series D Mirroring Preferred Stock will automatically terminate effective concurrently with the Reverse Stock Split and such shares will resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series D Mirroring Preferred Stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:11pt;">A copy of the Certificate of Amendment is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c286d0f2_e7bf_4dc3_8ac9_123471c60e0c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.01&#160;&#160;&#160;&#160;&#160;Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 22, 2022, the Company issued a press release announcing the Reverse Stock Split and increase in authorized shares of common stock. A copy of such press release is attached to this Current Report on Form 8-K as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_88bfa4e6_50fe_456c_95a8_7d54d21f5599"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="font-size:11pt;">Exhibits</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:21.65%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:76.17%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:21.65%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:76.17%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="rsls-20221221xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Restated Certificate of Incorporation, as amended, of ReShape Lifesciences Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:76.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="rsls-20221221xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated December 22, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:76.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_cfb07d43_aa3f_408a_b5ac_a4173c57de89"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt;"><span style="font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:39.6pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:52.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RESHAPE LIFESCIENCES INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Paul F. Hickey</p></td></tr><tr><td style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paul F. Hickey</p></td></tr><tr><td style="vertical-align:bottom;width:47.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Dated: December 28, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "rsls-20221221x8k.htm", "description": "8-K", "secsgml_size_bytes": 37494}]
{"company-data": {"conformed-name": "ReShape Lifesciences Inc.", "cik": "0001427570", "assigned-sic": "3841", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37897", "film-number": "221494762"}, "business-address": {"street1": "1001 CALLE AMANECER", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673", "phone": "949-429-6680"}, "mail-address": {"street1": "1001 CALLE AMANECER", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673"}, "former-company": {"former-conformed-name": "OBALON THERAPEUTICS INC", "date-changed": "20080220"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
​
FORM
8-K
​
CURRENT REPORT
​
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
December 21, 2022
​
RESHAPE LIFESCIENCES INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
Delaware
1-37897
26-1828101
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
​
​
​
1001 Calle Amanecer
San Clemente
,
CA
​
92673
(Address of principal executive offices)
​
(Zip Code)
​
(
949
)
429-6680
(Registrant's telephone number, including area code)
​
Not applicable
(Former name or former address, if changed since last report.)
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
​
Title of Class
Trading Symbol
Name of Exchange on which Registered
Common stock, $0.001 par value per share
RSLS
The
Nasdaq
Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
Item 3.03     Material Modification to Rights of Security Holders.
The information contained in Item 5.03 below is incorporated by reference into this Item 3.03.
​
Item 5.03     Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 21, 2022, ReShape Lifesciences Inc. (the "Company") filed a Certificate of Amendment (the "Certificate of Amendment") to its Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse split of the Company's outstanding common stock, $0.001 par value per share (the "Reverse Stock Split"). The Reverse Stock Split became effective for trading purposes upon the commencement of trading on December 23, 2022, at which point the Company's common stock began trading on a split adjusted basis on the Nasdaq Capital Market. As a result of the Reverse Stock Split, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share.
As a result of the Reverse Stock Split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the Company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.
The Certificate of Amendment also increased the number of shares of common stock that the Company is authorized to issue under the Certificate of Incorporation from 100,000,000 to 300,000,000 shares. The Reverse Stock Split does not reduce the number of authorized shares of common stock and preferred stock under the Certificate of Incorporation. Therefore, the effect of the Reverse Stock Split is to increase the number of shares of common stock and preferred stock available for issuance relative to the number of shares issued and outstanding.  The Reverse Stock Split will not alter the par value of the common stock or preferred stock or modify any voting rights or other terms of the common stock or any series of preferred stock. The Reverse Stock Split and increase in authorized shares of common stock were approved by the Company's stockholders at its annual meeting of stockholders held on December 14, 2022.
As set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Mirroring Preferred Stock of the Company, the Series D Mirroring Preferred Stock will automatically terminate effective concurrently with the Reverse Stock Split and such shares will resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series D Mirroring Preferred Stock.
A copy of the Certificate of Amendment is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
​
Item 8.01     Other Events.
On December 22, 2022, the Company issued a press release announcing the Reverse Stock Split and increase in authorized shares of common stock. A copy of such press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
​
Item 9.01     Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
3.1
​
Fifth Amendment to Restated Certificate of Incorporation, as amended, of ReShape Lifesciences Inc.
99.1
​
Press release dated December 22, 2022
104
​
Cover Page Interactive Data File (embedded within the Inline XBRL document)
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
RESHAPE LIFESCIENCES INC.
​
​
​
​
By:
/s/ Paul F. Hickey
​
​
Paul F. Hickey
​
​
President and Chief Executive Officer
​
Dated: December 28, 2022
​
​